Andrea Odersky
Overview
Explore the profile of Andrea Odersky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korste S, Settelmeier S, Michel L, Odersky A, Stock P, Reyes F, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047026
Cancer survival rates have increased significantly because of improvements in therapy regimes and novel immunomodulatory drugs. Recently, combination therapies of anthracyclines and immune checkpoint inhibitors (ICIs) have been proposed to...
2.
Michel L, Helfrich I, Hendgen-Cotta U, Mincu R, Korste S, Mrotzek S, et al.
Eur Heart J
. 2021 Aug;
43(4):316-329.
PMID: 34389849
Aims: Cardiac immune-related adverse events (irAEs) from immune checkpoint inhibition (ICI) targeting programmed death 1 (PD1) are of growing concern. Once cardiac irAEs become clinically manifest, fatality rates are high....
3.
Heinen-Weiler J, Hasenberg M, Heisler M, Settelmeier S, Beerlage A, Doepper H, et al.
J Cachexia Sarcopenia Muscle
. 2021 Jun;
12(4):933-954.
PMID: 34120411
Background: Cardioprotection by preventing or repairing mitochondrial damage is an unmet therapeutic need. To understand the role of cardiomyocyte mitochondria in physiopathology, the reliable characterization of the mitochondrial morphology and...
4.
Jeanclos E, Knobloch G, Hoffmann A, Fedorchenko O, Odersky A, Lamprecht A, et al.
FEBS Lett
. 2020 Apr;
PMID: 32324254
Pyridoxal 5'-phosphate (PLP) is an essential cofactor for neurotransmitter metabolism. Pyridoxal phosphatase (PDXP) deficiency in mice increases PLP and γ-aminobutyric acid levels in the brain, yet how PDXP is regulated...
5.
Han Y, Lindner S, Bei Y, Dorado Garcia H, Timme N, Althoff K, et al.
Cancer Lett
. 2019 Jan;
445:24-33.
PMID: 30611741
Medulloblastoma is the most prevalent central nervous system tumor in children. Targeted treatment approaches for patients with high-risk medulloblastoma are needed as current treatment regimens are not curative in many...
6.
Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, et al.
Oncotarget
. 2017 Apr;
8(17):27882-27891.
PMID: 28427187
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role....
7.
Pajtler K, Sadowski N, Ackermann S, Althoff K, Schonbeck K, Batzke K, et al.
Oncotarget
. 2016 Dec;
8(4):6730-6741.
PMID: 28036269
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that promotes G2/M-phase transition, is expressed in elevated levels in high-risk neuroblastomas and correlates with unfavorable patient outcome. Recently, we and others...
8.
Henssen A, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, et al.
Oncotarget
. 2016 Nov;
8(1):430-443.
PMID: 27888795
Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy...
9.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al.
Clin Cancer Res
. 2015 Dec;
22(10):2470-81.
PMID: 26631615
Purpose: Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models...
10.
Lindner S, Bachmann H, Odersky A, Schaefers S, Klein-Hitpass L, Hero B, et al.
Biomed Rep
. 2015 Jul;
3(4):443-446.
PMID: 26171145
Maintenance of telomere length is a critical hallmark of malignant transformation. While silenced in somatic cells, telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase, is frequently overexpressed in malignant...